| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 301.67 | 48.3% |
| Total Income | 301.67 | 48.3% |
| Expenditure | 423.02 | 34.5% |
| PBT | -111.70 | 17.7% |
| Net Profit | -112.08 | 17.8% |
| OPM | -40.23% | 14.35pp |
| NPM | -37.15% | 9.62pp |
| EPS | -0.85 | 10.4% |
Guardant Health Reports Q1 2026 Revenue Up 48% and Raises 2026 Guidance
08 May 2026 · 8 May, 1:50 am
Summary
Guardant Health reported a strong first quarter in 2026, with revenue reaching $301.7 million, a 48% increase compared to the previous year. The growth was primarily driven by significant increases in Oncology and Screening revenues. The company has raised its full year 2026 revenue guidance to $1.30 to $1.32 billion, reflecting confidence in continued growth. Management is focused on scaling commercial infrastructure and expanding collaborations to broaden reach in cancer screening and drive long-term value creation.
Key Highlights
- 1
Guardant Health's first quarter 2026 revenue increased by 48% year-over-year, driven by strong performance in Oncology and Screening.
- 2
Oncology revenue reached $205.0 million, representing a 36% increase, with approximately 86,000 oncology tests, up by 47%.
- 3
Screening revenue grew over 600% to $41.6 million, with approximately 44,000 Shield screening tests compared to $5.7 million in the prior year period.
- 4
Biopharma & Data revenue increased by 17% to $53.0 million.
- 5
The company's non-GAAP gross margin was 66%, compared to 65% for the first quarter of 2025.
- 6
Guardant Health raised its full year 2026 revenue guidance to $1.30 to $1.32 billion, representing growth of 32% to 34%.
Management Comments
Helmy Eltoukhy
Our first-quarter revenue increased 48% year over year, reflecting strong momentum across the Guardant portfolio. Oncology testing volumes continued to accelerate, reaching 86,000 in the quarter, up 47% year over year. Guardant360 Liquid and Guardant360 Tissue demonstrated significant growth, and we saw strong receptivity to our expansion into therapy response monitoring with Guardant Reveal. We believe these trends, driven by our Smart platform and InfinityAI offerings, position us well for sustained growth and for extending our leadership in precision oncology.
AmirAli Talasaz
We are pleased with our progress with Shield, including strong volume momentum exiting the first quarter. We expect sustained volume growth as we further build out our commercial infrastructure and expand collaborations with Quest and other partners. With a disciplined focus on execution as we scale, we are well positioned to broaden our reach in cancer screening and drive long-term value creation.
Informational and educational content only. Not investment advice.